Is AOD-9604 FDA-approved?

No. AOD-9604 is not FDA-approved for any indication. It received FDA Generally Recognized as Safe (GRAS) status for use as a food ingredient under a different context but is not approved as a drug. Compounded AOD-9604 is not FDA-approved and physician evaluation is required.

How does it differ from HGH?

Full HGH raises IGF-1 (associated with cancer risk concerns), can cause insulin resistance, and has a broad systemic effect. AOD-9604 is a fragment — it targets fat metabolism specifically without IGF-1 elevation or glucose effects based on current available data.

What does the evidence show?

The evidence base is primarily preclinical — animal studies demonstrating fat loss effects. Human trials conducted by Monash University showed safety but limited efficacy with oral administration. Injectable compounded AOD-9604 has not undergone equivalent human trials. Your physician will review the evidence with you.

Can I use it with GLP-1 medications?

This combination has not been studied. Your physician will evaluate whether it is appropriate for your situation and health history.

How is it administered?

Typically subcutaneous injection, usually daily. Your physician will determine the appropriate protocol.

What should I expect?

Given the limited human evidence expectations should be realistic. Your physician will discuss likely outcomes and help you determine whether the risk-benefit profile makes sense for your goals.

Part of the pillar guide: Peptide Therapy — Complete Guide

kindr

HGH Fragment 176-191 · Fat Metabolism

The fat-burning fragment of HGH — without the insulin effects.

AOD-9604 is a modified fragment of human growth hormone — specifically the region responsible for fat metabolism. Studied for its ability to stimulate lipolysis and inhibit lipogenesis without the blood sugar and IGF-1 effects associated with full HGH administration.

Request Physician Evaluation →

AOD-9604 evidence is primarily preclinical. Human trial data is limited. Physician evaluation required and prescription not guaranteed.

Fragment

Amino acids 176-191 of the HGH C-terminus — the fat-metabolizing region

No IGF-1

Does not raise IGF-1 levels — a key differentiator from full HGH

Preclinical

Evidence base — animal studies and early human research

The science behind AOD-9604.

Preclinical disclaimer: The evidence base for AOD-9604 is primarily animal studies and limited human data. Injectable compounded AOD-9604 has not undergone the same clinical trial evaluation as FDA-approved medications. Individual results may vary and physician evaluation is required.

AOD-9604 (Anti-Obesity Drug 9604) was originally developed by Monash University in Australia as a potential obesity treatment. It consists of amino acids 176-191 of the human growth hormone C-terminal region — the specific segment identified as responsible for HGH's fat-metabolizing effects. The hypothesis: isolate the fat-burning properties of HGH without the metabolic side effects.

In animal studies AOD-9604 stimulates lipolysis (breakdown of stored fat) and inhibits lipogenesis (new fat formation) through beta-3 adrenergic receptor activity. Critically it does not appear to raise IGF-1 levels or affect blood sugar — the two primary concerns with full HGH administration. This selective fat metabolism profile is the reason for its clinical interest.

Monash University conducted Phase 2 human trials for AOD-9604 as an oral obesity treatment. The trials showed the compound was safe and well-tolerated but did not demonstrate statistically significant weight loss at the doses studied orally. The injectable form used in current compounding practice has not been evaluated in the same way. Clinical evidence remains limited.

Three key properties

No IGF-1 effect

Unlike full HGH which raises IGF-1 (associated with cancer risk concerns at high levels), AOD-9604 does not appear to stimulate IGF-1 production — a significant safety distinction.

No glucose effects

Full HGH can cause insulin resistance. AOD-9604 does not appear to affect insulin sensitivity or blood glucose — making it potentially suitable for a broader patient population.

Targeted lipolysis

Animal research shows AOD-9604 preferentially targets visceral fat — the metabolically active abdominal fat most associated with metabolic risk — though human data for this specificity is limited.

AOD-9604 alongside GLP-1 therapy.

GLP-1 medications are highly effective for overall weight loss but do not specifically target fat over muscle. AOD-9604 — if the preclinical lipolysis data translates to humans — could theoretically complement GLP-1 therapy by supporting fat-specific metabolism during the weight loss period.

This combination represents an area of clinical interest given the prevalence of GLP-1 users seeking to optimize fat loss while preserving lean mass. Your physician will evaluate whether this combination is appropriate for your specific situation.

Important: The combination of AOD-9604 and GLP-1 medications has not been studied in clinical trials. Your physician will make an individualized determination.

Who benefits most

Adults seeking fat metabolism support
GLP-1 users wanting additional fat-specific support
People with stubborn visceral fat
Those concerned about HGH side effects (AOD-9604 avoids them)
Women in menopause with abdominal fat accumulation

Contraindications

Active malignancy or cancer history
Pregnancy or breastfeeding
Known hypersensitivity

Side effects (based on available data)

Generally well-tolerated
Injection site reactions
Headache (rare)
Flushing (rare)
No glucose effects reported
No IGF-1 elevation reported

Start your AOD-9604 evaluation.

Complete the form below. A physician will review and respond within 24 hours.

Full name *

Email *

Phone *

Date of birth *

State *

Primary concern *

Current weight (lbs) *

Height *

Current medications or supplements *

Medical conditions (select all that apply)

Type 2 diabetesHypertensionHigh cholesterolSleep apneaPCOSThyroid conditionNone of the above

Prior experience with HGH or peptides?

Additional information

I consent to the collection and use of my health information for evaluation purposes. I understand this service is not a substitute for emergency care.I understand AOD-9604 is not FDA-approved and that a prescription is not guaranteed. I consent to physician evaluation.

Form data is transmitted securely. If submission fails, a mailto fallback will open with your details pre-filled.

Frequently asked questions.

AOD-9604 is a modified fragment of human growth hormone — specifically amino acids 176-191 of the HGH C-terminus. It was identified as the region responsible for HGH's fat metabolizing effects and studied as a potential obesity treatment. It does not raise IGF-1 or affect blood sugar — distinguishing it from full HGH.

The fat-metabolizing fragment.
Physician-supervised.

Request Physician Evaluation →

AOD-9604 is not FDA-approved. Compounded AOD-9604 is not FDA-approved and has not been evaluated by the FDA for safety, efficacy, or quality. Prescription requires physician evaluation and is not guaranteed. Individual results vary. This information is for educational purposes and does not constitute medical advice. kindr Health does not guarantee outcomes. All medications are prescribed by independent licensed physicians through Arora Health & Aesthetics, LLC. Compounded by VialsRX, Houston TX — licensed 503A pharmacy. Services available in all 50 states where permitted by law.

GLP-1 Complete Bundle →Retatrutide →GHK-Cu →Sermorelin →

Keep reading

GLP-1 Complete program

Wraparound metabolic support for sustained weight management.

Read GLP-1 Complete program →

Semaglutide

GLP-1 agonist with the largest evidence base for weight loss.

Read Semaglutide →

Metabolic Reset

Lab-driven program to address insulin, cortisol, and body composition.

Read Metabolic Reset →

Medically reviewed by Dr. Ana Lisa Carr, MD, MBA
Board-Certified Family Medicine Physician · Lead Provider / Medical Reviewer
NPI 1689841744 · Last reviewed: May 10, 2026

Latest from the Journal

Weight & metabolism
HRT vs GLP-1 for menopause weight loss: which is right for you?
Hormone therapy addresses the hormonal causes of midlife weight gain. GLP-1s like semaglutide target appetite and metabolism. Here is how they differ — and when to use one, the other, or both.
Read HRT vs GLP-1 for menopause weight loss: which is right for you? →
Lifestyle
Strength training in menopause: the single most important habit after 40
Estrogen loss accelerates muscle and bone decline. Resistance training — done correctly — is the closest thing we have to a medication for it.
Read Strength training in menopause: the single most important habit after 40 →
Perimenopause
Understanding perimenopause: the years before menopause
Perimenopause can begin in your late 30s or 40s and last up to a decade. Here is what is happening hormonally and what actually helps.
Read Understanding perimenopause: the years before menopause →